Drugs / SGT-94
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01517464 | Jan 2012 → Dec 2015 | neoplasm | SynerGene Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SGT-94 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01517464 ↗ |
| Route | Intravenous | “Intravenous infusion will occur over 1 to 2.5 hours” NCT01517464 ↗ |